Phase II study of nedaplatin and amrubicin as first‐line treatment for advanced squamous cell lung cancer
BACKGROUND: The first‐line treatment for squamous cell lung cancer (SCC) has not necessarily been established; however, our previous exploratory study suggested that the combination of nedaplatin and amrubicin would be a promising treatment approach for patients with SCC. Therefore, a phase II study...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718021/ https://www.ncbi.nlm.nih.gov/pubmed/31309738 http://dx.doi.org/10.1111/1759-7714.13134 |